NASDAQ:NTHI Neonc Technologies Q2 2025 Earnings Report $4.54 -0.21 (-4.38%) As of 11:41 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neonc Technologies EPS ResultsActual EPS-$0.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANeonc Technologies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeonc Technologies Announcement DetailsQuarterQ2 2025Date8/18/2025TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsNeonc Technologies' next earnings date is estimated for Friday, August 14, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Neonc Technologies Earnings HeadlinesFrom Nokia to NeOnc: The Stocks Dominating Screens as Volume SpikesJune 13 at 2:24 PM | markets.businessinsider.comNeOnc Technologies secures $5M private placement via Series A preferred stockJune 13 at 2:24 PM | msn.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.June 15 at 1:00 AM | Banyan Hill Publishing (Ad)NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different StrategyMay 31, 2026 | finance.yahoo.comThe Next Great AI Revolution May Be Drug DeliveryMay 29, 2026 | globenewswire.comThe Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology PlatformsMay 21, 2026 | usatoday.comSee More Neonc Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email. Email Address About Neonc TechnologiesNeonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.View Neonc Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the ShowWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors Ears Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
